Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review presents standardized methods for assessing and tracking hair loss in alopecia areata but reports no clinical results, with the authors noting time limitations in clinical practice.

This study found that nuclear androgen receptors are not necessary for androgen self-administration, suggesting that plasma membrane receptors might be involved.

This study found a decreased number of follicular melanocytes in patients with alopecia areata, though it remains unclear if this decrease is due to autoimmune attack or rapid hair cycling.

This article discusses alopecia areata occurring during Interferon Alpha-2b/Ribavirin therapy and reports no new clinical results.

This review discusses the clinical characteristics, diagnosis, and treatment of alopecia areata, exploring potential environmental, immunological, and genetic factors involved in its development, but reports no new research findings.

This article reviews the skin effects of anabolic-androgenic steroid use in athletes but reports no clinical results.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

In this study, single-cell sequencing revealed clonal expansions of CD4+ and CD8+ T cells in murine and human alopecia areata, supporting the development of predictive models for human disease.

This study reports two cases of hair loss outcomes in patients using dupilumab for atopic dermatitis, with one showing improvement in alopecia universalis and another experiencing worsening of alopecia totalis.

This study found an association between vertex baldness and prostate cancer, especially for high-grade tumors in men aged 60-69, suggesting a possible shared androgen pathway.

This study reported that some pediatric patients with alopecia areata experienced hair regrowth with dupilumab treatment, particularly those with concomitant atopic dermatitis, suggesting dupilumab may be beneficial when traditional therapies fail.

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

This study found that an earlier onset of androgenetic alopecia, especially in a frontal balding pattern, was significantly associated with an increased risk of prostate cancer among men at a Veterans Affairs Hospital.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

This study identified associations between alopecia areata and posttraumatic stress disorder, obesity, and alcohol use, reinforcing the need for psychiatric and alcohol use screening in these patients.

This study explores how children perceive peers with alopecia areata and the social effects associated with the condition, but it reports no new experimental findings.

This review discusses how environmental factors like lifestyle, nutrition, and vitamin deficiencies may influence autoimmune diseases such as MS, SLE, and AA, highlighting associations with vitamin D levels and dietary interventions, but notes a lack of conclusive evidence for their roles in disease pathogenesis.

This study found that alopecia areata severity significantly influences the health-related quality of life impacts and treatment patterns among affected individuals.

This study found that although both adults and adolescents with alopecia areata experience a significant quality of life impact from ≥50% scalp hair loss, the impact is greater for adolescents, as indicated by their higher Dermatology Life Quality Index scores.

This study found that topical simvastatin induced remission and hair regrowth in a mouse model of alopecia areata, potentially by modulating T cell activity and reducing pro-inflammatory cytokine signaling.

This study found that clinicians treating alopecia areata prioritize JAK inhibitor treatments with higher efficacy and faster initial hair growth, regardless of dosing frequency, and preferred the treatment option with ritlecitinib 50-mg data the least among several blinded profiles.

The measures for eyebrow and eyelash hair loss in severe Alopecia Areata are reliable and useful for clinical trials.

Children with alopecia areata often face more stress and depression, especially related to separation, which can affect their condition.

This case study reported that acupuncture therapy successfully resolved long-standing alopecia areata in a 61-year-old male after nine months of treatment, suggesting potential efficacy without pharmacological intervention.

This study identified CD28 as a promising drug target for treating alopecia areata, using a multi-omics approach to highlight its role in immune regulation and linking it to favorable safety profiles, thus offering a strategy for autoimmune target discovery.

This study identified CD28 as a potential drug target in treating alopecia areata by linking immune signaling pathways to local inflammation, highlighting belatacept as a promising treatment option due to minimal adverse effects and providing insights into autoimmune target discovery.

Alopecia areata involves complex immune cell interactions, especially between CD8+ T cells and macrophages, which could help develop new treatments.

This review highlights significant advances in understanding and treating Alopecia Areata, emphasizing the effectiveness of JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib for systemic treatment, while also noting ongoing research into new therapeutic approaches such as stem cell therapy and energy-assisted drug delivery.

This study reports the prescribing preferences of UK dermatologists for treating various hair loss conditions, noting that topical corticosteroids for mild to moderate alopecia areata and topical minoxidil for female pattern hair loss are commonly used first-line treatments.